Alana Hippensteele, Managing Editor

Outpatient models are emerging as feasible alternatives to traditional inpatient care, offering potential benefits such as reduced hospitalization, improved social well-being, and cost savings.

Two clinical trials with MRD monitoring may be practice changing: TRACERx and AEGEAN.

ASCO is prioritizing the expansion of pharmacist involvement in its organization by recognizing pharmacists' contributions to safety standards, quality improvement initiatives, and certification programs.

Gut microbiome research is no longer an obscure field in cancer care.

These therapies are being investigated in earlier lines, with several new treatments in development.

The guidelines emphasize the importance of vaccination, risk assessment, and preparedness for immunocompromised patients who are traveling post-transplant.

The KEYNOTE-756 and CheckMate 7FL trials show this combination improves pathological complete response rates in this patient population.

Pharmacogenomic testing can help identify patients' genetic profiles, revealing why certain drugs may be less effective or cause adverse effects.

The FDA faces a multitude of challenges in regulating artificial intelligence (AI) and machine learning (ML) medical devices.

The work of Obstetrician Ignaz Semmelweis lives on in medical protocols today.

The trial demonstrated that the combination of lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) significantly improves progression-free survival and objective response rates compared to TACE alone.

The efficacy and safety profiles of CAR T-cell and bispecific antibody therapies have led to their investigation in earlier lines of therapy, with several new treatments in development.

Data from the second interim analysis of the DETECT V trial, presented at ESMO Congress 2024, suggest that a chemotherapy-free regimen combining dual HER2-targeted therapy with endocrine therapy, particularly with the addition of ribociclib, may be an effective treatment for patients.

At ESMO Congress 2024, Shuji Ogino, MD, PhD, MS, explained that the rising incidence of young-onset cancer may be due to generational risk factors such as lifestyle, diet, and environmental changes, emphasizing the need for long-term research and follow up to understand early-life influences on cancer development.

Overall survival results from the phase 3 KEYNOTE-522 study provide evidence of improved long-term outcomes from this pembrolizumab-based regimen.

Clinical research presented at ESMO 2024 highlights the significant survival benefits of perioperative and neoadjuvant immunotherapy with nivolumab and nivolumab plus ipilimumab, while emphasizing the role of biomarkers such as ctDNA and KRAS mutations in guiding treatment decisions.

An ESMO 2024 presentation explores the growing role of the gut microbiome in immunotherapy response, emerging diagnostic tools such as PCR chips, and innovative therapies such as fecal microbiota transplantation and microbiome-preserving strategies to improve patient outcomes.

The gut and intratumoral microbiota influence cancer development, progression, and treatment responses, highlighting the potential for treatment strategies that leverage these microbial interactions to enhance cancer therapies.

Disparities continue in younger patients, raising the need for novel interventions to mitigate challenges associated with younger age at diagnosis.

The financial burden has increased significantly since 2015.

Axatilimab-csfr (Niktimvo, Incyte Corporation) is a colony stimulating factor-1 receptor-blocking antibody for the treatment of chronic graft-versus-host disease (cGVHD).

Findings from 2 large datasets suggest hormone therapy may reduce Alzheimer risk, hippocampal atrophy, and cerebrovascular disease.

Significant commonalities between type 2 diabetes and neurodegenerative disorders suggest that treatments effective for one condition may benefit the other.

Understanding and accounting for linguistic diversity is critical in diagnostics and treatment for dementia.

Both economic factors and supply chain fragility play a role.

Pharmacists can also play a role in SDOH by replacing drug delivery with something else, such as food or transportation delivery, according to speakers at the ATOPP conference.

The European Union (EU) has successfully created a competitive market for biosimilars, while the US faces challenging market dynamics and tactics by pharmacy benefit managers that hinder the adoption of lower-cost therapies.

Collaboration between community centers and academic medical centers can improve patient access to these complex therapies.

Laura Bray, founder of Angels for Change, explains that addressing the 4 key economic causes to drug shortages can also help lead to effective solutions long-term.

Site-of-care considerations can pose challenges with these therapies.